A randomized, double blind, parallel group, placebo controlled, multi center dose ranging study of solifenacin succinate in combination with tamsulosin hydrochloride compared with solifenacin succinate monotherapy and tamsulosin hydrochloride monotherapy in males with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)

Trial Profile

A randomized, double blind, parallel group, placebo controlled, multi center dose ranging study of solifenacin succinate in combination with tamsulosin hydrochloride compared with solifenacin succinate monotherapy and tamsulosin hydrochloride monotherapy in males with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Mar 2017

At a glance

  • Drugs Solifenacin (Primary) ; Tamsulosin (Primary)
  • Indications Benign prostatic hyperplasia; Lower urinary tract symptoms
  • Focus Therapeutic Use
  • Acronyms SATURN
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 01 Aug 2012 New source identified and integrated (German Clinical Trials Register DRKS00004046).
    • 21 Jun 2012 Additional locations added as reported by European Clinical Trials Database record.
    • 10 Dec 2008 Actual patient number (919) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top